containing
cloperastine fendizoate produced by Almirall.
Early history Almirall SA was founded in 1944 in Spain. In 1979, the company launched gastroprokinetic clebopride in Spain, the first product from the company's internal R&D team. In 1984, the business launched antacid product,
almagate, in Spain, as well as
anti-inflammatory piketoprofen in 1985 and antihistamine
ebastine and
cinitapride in 1985. In the same year, Almirall opened its first subsidiary, based in Belgium. In 1992 the company launched
aceclofenac and a year later opened its second foreign subsidiary, in Portugal. The company's new headquarters were opened in Barcelona, in 1994. In 1997 Almirall and
Prodesfarma merged their interests.
Further expansion In 2000 the FDA approved anti-migraine agent
almotriptan. A year later the company opened its Mexican subsidiary as well as acquiring its French affiliate. Beginning in 2002, Almirall opened a series of European-based subsidiaries; Italy (2002), Germany (2003), Austria, Poland, the United Kingdom, Ireland and Switzerland (2008), Nordic Countries (2010) and Netherlands (2013). In 2005 the business acquired the commercial rights for
Sativex in
Europe for the treatment of spasticity associated to
multiple sclerosis. In 2006, the company opened its new R&D Centre based in
Sant Feliu de Llobregat as well as the acquisition of the Centre of Excellence for Inhalation Technology. In 2007, the company floated on the Spanish stock market, as well as acquiring European dermatology specialist, Hermal. The company also acquired a portfolio of eight products from
Shire plc. In 2011, Almirall launched
Actikerall prescribed for the local treatment of
actinic keratosis. In 2012, Almirall opened its first North America subsidiary, based in Canada following the acquisition of another specialist dermatology company, Aqua Pharmaceuticals. The company launched
linaclotide in Europe (Constella) for
irritable bowel syndrome with
constipation (IBS-C) and opened its Netherlands subsidiary. In May 2022, a new generational change took place within the founding family, with the replacement of Jorge Gallardo Ballart by his son Carlos Gallardo Piqué at the head of the non-executive presidency of the company. Six months later, Carlos Gallardo also assumed the executive management. == Activities ==